Wethington Stephanie L, Herzog Thomas J, Seshan Venkatraman E, Bansal Nisha, Schiff Peter B, Burke William M, Cohen Carmel J, Wright Jason D
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
Cancer. 2008 Dec 15;113(12):3298-306. doi: 10.1002/cncr.23957.
Fallopian tube cancers are rare neoplasms. These malignancies are thought to behave biologically and clinically like ovarian cancer. The purpose of this study was to compare the clinical behavior and outcome of fallopian tube and ovarian cancer.
The Surveillance, Epidemiology, and End Results database was reviewed to identify women with tumors of the fallopian tube (FT) and ovary (OV) diagnosed between 1988 and 2004. Demographic and clinical data were compared, and the impact of tumor site on survival was analyzed using Cox models and the Kaplan-Meier method.
A total of 55,825 patients were identified, 1576 (3%) with FT and 54,249 (97%) with OV cancer. FT patients were more likely to present with early stage tumors (P < .001). Among FT patients, 47% had stage I/II tumors compared with 29% of OV cancers. In an adjusted Cox model of all patients, cancer-specific mortality was 48% lower in FT patients (hazard ratio, 0.52; 95% confidence interval [CI], 0.48-0.56) compared with OV cancer. Among patients with FT tumors, advanced age and stage were independent predictors of decreased survival. When stratified by stage, survival was similar for stage I and II tumors, but stage III and IV FT patients had an improved survival. The 5-year survival for stage III FT cancer was 54% (95% CI, 48%-60%), compared with 30% (95% CI, 29%-31%) for OV.
Fallopian tube cancers present earlier and at advanced stage have a better overall survival than primary ovarian malignancies. Future clinical trials should recognize the possible distinct clinical behavior of fallopian tube cancers.
输卵管癌是罕见肿瘤。这些恶性肿瘤在生物学行为和临床特征上被认为与卵巢癌相似。本研究的目的是比较输卵管癌和卵巢癌的临床行为及预后。
回顾监测、流行病学和最终结果数据库,以确定1988年至2004年间被诊断为输卵管(FT)和卵巢(OV)肿瘤的女性。比较人口统计学和临床数据,并使用Cox模型和Kaplan-Meier方法分析肿瘤部位对生存的影响。
共识别出55825例患者,其中1576例(3%)为输卵管癌,54249例(97%)为卵巢癌。输卵管癌患者更易出现早期肿瘤(P <.001)。在输卵管癌患者中,47%为Ⅰ/Ⅱ期肿瘤,而卵巢癌患者中这一比例为29%。在所有患者的校正Cox模型中,与卵巢癌相比,输卵管癌患者的癌症特异性死亡率低48%(风险比,0.52;95%置信区间[CI],0.48 - 0.56)。在输卵管肿瘤患者中,高龄和晚期是生存降低的独立预测因素。按分期分层时,Ⅰ期和Ⅱ期肿瘤患者的生存率相似,但Ⅲ期和Ⅳ期输卵管癌患者的生存率有所提高。Ⅲ期输卵管癌的5年生存率为54%(95% CI,48% - 60%),而卵巢癌为30%(95% CI,29% - 31%)。
输卵管癌发病较早,晚期患者的总生存率高于原发性卵巢恶性肿瘤。未来的临床试验应认识到输卵管癌可能具有的独特临床行为。